標(biāo)題: Titlebook: Entry Inhibitors in HIV Therapy; Jacqueline D. Reeves,Cynthia A. Derdeyn Book 2007 Birkh?user Basel 2007 AIDS.HIV.HIV Therapy.HIV infectio [打印本頁(yè)] 作者: enamel 時(shí)間: 2025-3-21 19:08
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy影響因子(影響力)
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy被引頻次
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy被引頻次學(xué)科排名
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy年度引用
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy年度引用學(xué)科排名
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy讀者反饋
書(shū)目名稱(chēng)Entry Inhibitors in HIV Therapy讀者反饋學(xué)科排名
作者: BLOT 時(shí)間: 2025-3-21 21:47 作者: 時(shí)代 時(shí)間: 2025-3-22 03:46 作者: 墻壁 時(shí)間: 2025-3-22 04:52 作者: CREEK 時(shí)間: 2025-3-22 09:48
Inhibitors that target gp120 interactions with coreceptor,ssays on human cell lines as syncytium inducing (SI) or non-syncytium inducing (NSI) [.]. NSI viruses predominate early after transmission, are capable of growth in primary macrophages (macrophage tropism), and fail to grow in most established human T cell lines. SI viruses, by contrast, are found i作者: 半球 時(shí)間: 2025-3-22 16:28 作者: 半球 時(shí)間: 2025-3-22 19:24
Entry inhibition of HIV-1 subtype C isolates, [.]. There is less information on how genetic variability might affect the efficacy of a newer class of anti-retrovirals, the entry or fusion inhibitors. This group comprises a diverse collection of compounds that target both viral and host cell components blocking virus attachment and/or fusion an作者: PACK 時(shí)間: 2025-3-22 21:36 作者: 重畫(huà)只能放棄 時(shí)間: 2025-3-23 01:31
Future clinical prospects for entry inhibitors,once (with the FDA approval of a membrane fusion inhibitor, enfuvirtide, in 2003) has this strategic approach resulted in a commercially available agent. Indeed, for more than 15 years, from 1987 to 2003, all available antiretroviral therapies targeted one of two HW-encoded enzymes, reverse transcri作者: Obsessed 時(shí)間: 2025-3-23 08:02 作者: 休戰(zhàn) 時(shí)間: 2025-3-23 10:00
,Targets for drug development — past and present,or effective treatment began urgently. This search was facilitated greatly by the discovery of the causative agent, the human immunodeficiency virus (HIV) [., .]. It was recognized early on that the replication cycles of other animal and human retroviruses depended on the virus-specific enzyme rever作者: Diverticulitis 時(shí)間: 2025-3-23 14:21 作者: 油膏 時(shí)間: 2025-3-23 19:28
HIV-1 entry inhibitors as microbicides,h outside and within the context of the commercial sex industry was identified early on as a major driving force for the catastrophic rate of infection now reported in many regions of the world [., .].作者: CORE 時(shí)間: 2025-3-24 01:59
Book 2007he development of this class of inhibitors as microbicidal therapy, and the success story of enfuvirtide from the bench to FDA approval. Both basic research findings and results of clinical studies are covered and linked together by a diverse panel of experts in the field..作者: cauda-equina 時(shí)間: 2025-3-24 05:02
Struktur und Form des Holzmarktes,oid disease progression [., .]. Together, these factors necessitate the continual development of new antiretroviral agents that can be utilized against resistant viruses or that in combination with other agents can provide superior viral suppression with less toxicity.作者: CUMB 時(shí)間: 2025-3-24 06:47
Mastocytosis (Urticaria Pigmentosa),h outside and within the context of the commercial sex industry was identified early on as a major driving force for the catastrophic rate of infection now reported in many regions of the world [., .].作者: enumaerate 時(shí)間: 2025-3-24 11:44 作者: Granular 時(shí)間: 2025-3-24 18:09
Auswirkungen auf die Zivilgesellschaft,ng-term toxicities require the continuous need to improve these classes of drugs and to develop new drugs with other targets. Therefore, a new generation of drugs has been recently developed to inhibit viral entry into the cell.作者: cleaver 時(shí)間: 2025-3-24 21:49 作者: Medley 時(shí)間: 2025-3-25 01:37
https://doi.org/10.1007/978-3-322-83568-0d to rise over time. For these reasons, there is a pressing need for new classes of antiretroviral agents that are effective against HIV-1 resistant or insensitive to current drugs and that have the potential for co-formulation in convenient dosing regimens.作者: FEAS 時(shí)間: 2025-3-25 05:10 作者: facilitate 時(shí)間: 2025-3-25 08:42
https://doi.org/10.1007/978-3-7091-3133-6have activity against HIV . by inhibiting the reverse transcriptase enzyme, such as suramin [.] and ribavirin [.]. However, clinical trials of these agents ultimately showed no clinical benefits in HIV-infected patients [., .].作者: Ccu106 時(shí)間: 2025-3-25 13:46 作者: 含鐵 時(shí)間: 2025-3-25 17:49
Attachment of human immunodeficiency virus to cells and its inhibition,XCR4 or CCR5) (reviewed in [.]). Then a chain of dynamic events take place that enable the viral nucleocapsid to penetrate within the target cell following the destabilization of membrane microenvironment and the formation of a fusion pore.作者: fluoroscopy 時(shí)間: 2025-3-25 22:22 作者: 茁壯成長(zhǎng) 時(shí)間: 2025-3-26 03:24
The utility of coreceptor typing in the clinic,determination, mixed tropism. For example, a single HIV plasma sample may contain R5 as well as X4 or R5X4 viruses. Population-based coreceptor typing assays cannot distinguish between truly dual tropic viral populations and those that are mixed. Therefore the detection of both R5 and X4 tropism in a sample is reported as dual/mixed (DM).作者: G-spot 時(shí)間: 2025-3-26 07:22 作者: CESS 時(shí)間: 2025-3-26 11:22
2296-6056 own.Focuses on real-world issues, such as virus phenotyping .Entry Inhibitors in HIV Therapy details the current status of this relatively new and very dynamic class of inhibitors, appealing to both the clinician and basic research scientist. A unique overview of obstacles and accomplishments is pre作者: Infraction 時(shí)間: 2025-3-26 12:44
2296-6056 of enfuvirtide from the bench to FDA approval. Both basic research findings and results of clinical studies are covered and linked together by a diverse panel of experts in the field..978-3-7643-7783-0Series ISSN 2296-6056 Series E-ISSN 2296-6064 作者: NAIVE 時(shí)間: 2025-3-26 19:42
Thorsten Halling,Julia Sch?fer,J?rg V?geleeference largely explains cell tropism. The importance of CCR5 in viral transmission and as a target for therapeutic intervention was underscored by the discovery of a 32-base pair deletion in the human CCR5 coding region (Δ32 mutation) which, when homozygous, prevents CCR5 surface expression and HI作者: 走調(diào) 時(shí)間: 2025-3-26 21:47
Classification and Diagnosis of Urticaria,g up to 30% difference within HIV-1 and up to 55% between HIV-1 and HIV-2 (www.hiv.lanl.gov). Most entry inhibitors have been designed and tested based on HIV-1 subtype B viruses, and would therefore be expected to be most effective against viruses of this genetic subtype. There are few studies that作者: assail 時(shí)間: 2025-3-27 02:25 作者: 概觀 時(shí)間: 2025-3-27 06:27
https://doi.org/10.1007/978-3-662-10733-1 for the treatment of HIV: the RTIs - either nucleoside or non-nucleoside - and PIs. Although combinations of these agents brought about dramatic improvements in HIV therapy, the limitations of therapeutic regimens based solely on RTIs and PIs were already evident and problematic when enfuvirtide en作者: ODIUM 時(shí)間: 2025-3-27 13:04
Inhibitors that target gp120 interactions with coreceptor,eference largely explains cell tropism. The importance of CCR5 in viral transmission and as a target for therapeutic intervention was underscored by the discovery of a 32-base pair deletion in the human CCR5 coding region (Δ32 mutation) which, when homozygous, prevents CCR5 surface expression and HI作者: JAMB 時(shí)間: 2025-3-27 15:20 作者: In-Situ 時(shí)間: 2025-3-27 19:10 作者: 引起 時(shí)間: 2025-3-28 01:05
Enfuvirtide: from basic science to FDA approval, for the treatment of HIV: the RTIs - either nucleoside or non-nucleoside - and PIs. Although combinations of these agents brought about dramatic improvements in HIV therapy, the limitations of therapeutic regimens based solely on RTIs and PIs were already evident and problematic when enfuvirtide en作者: blackout 時(shí)間: 2025-3-28 04:39 作者: 過(guò)于平凡 時(shí)間: 2025-3-28 10:00
Entry Inhibitors in HIV Therapy978-3-7643-7783-0Series ISSN 2296-6056 Series E-ISSN 2296-6064 作者: Override 時(shí)間: 2025-3-28 14:30 作者: 烤架 時(shí)間: 2025-3-28 18:22
Auswirkungen auf die Zivilgesellschaft,fastest evolving among many other human pathogens. Viral heterogeneity is one of the classical means by which HIV evades the host immune system, and also leads to the resistance to various antiretroviral regimens. Highly active antiretroviral therapy to treat HIV-infected patients is mainly based on作者: Working-Memory 時(shí)間: 2025-3-28 18:47
https://doi.org/10.1007/978-3-662-60570-7tiated by specific binding interactions between glycoproteins in the viral envelope and appropriate receptors on the cell surface. In the case of HIV-1, attachment of virions to the cell surface is attributed to a high affinity interaction between envelope spike glycoproteins (Env, composed of the s作者: cinder 時(shí)間: 2025-3-29 00:44
https://doi.org/10.1007/978-3-322-83568-0s. However, four classes (nucleoside/nucleotide and non-nucleoside reverse transcriptase, protease, and fusion inhibitors) including 24 approved drugs are still inadequate and treatment failures continue to occur. Factors contributing to such failures include: the emergence of drug-resistant strains作者: enterprise 時(shí)間: 2025-3-29 04:49
